[
    [
        {
            "time": "",
            "original_text": "看好评级医药生物行业2018年三季报业绩前瞻：医药需求刚性 预计增长保持稳健",
            "features": {
                "keywords": [
                    "医药",
                    "生物",
                    "三季报",
                    "业绩",
                    "需求刚性",
                    "增长",
                    "稳健"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "看好评级医药生物行业2018年三季报业绩前瞻：医药需求刚性 预计增长保持稳健",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-12",
            "original_text": "【申万宏源医药闫一天团队】20181012周观点：医药需求刚性，预计增长保持稳健——医药生物行业2018年三季报业绩前瞻",
            "features": {
                "keywords": [
                    "申万宏源",
                    "医药",
                    "三季报",
                    "需求刚性",
                    "增长",
                    "稳健"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【申万宏源医药闫一天团队】20181012周观点：医药需求刚性，预计增长保持稳健——医药生物行业2018年三季报业绩前瞻",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医药健康行业周报：科伦药业产业布局深度点评",
            "features": {
                "keywords": [
                    "医药健康",
                    "科伦药业",
                    "产业布局",
                    "深度点评"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药健康"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药健康行业周报：科伦药业产业布局深度点评",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "华兰生物：目前国内的四价流感疫苗为公司独家供应",
            "features": {
                "keywords": [
                    "华兰生物",
                    "四价流感疫苗",
                    "独家供应"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物：目前国内的四价流感疫苗为公司独家供应",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "47股获券商买入评级，利亚德目标涨幅达153.49%",
            "features": {
                "keywords": [
                    "券商",
                    "买入评级",
                    "利亚德",
                    "目标涨幅"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "多元行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "47股获券商买入评级，利亚德目标涨幅达153.49%",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-15",
            "original_text": "【太平洋证券今日早读】固收：利率债短端机会更大，密切关注政策转向的可能性|华兰生物、联得装备公司点评20181015",
            "features": {
                "keywords": [
                    "太平洋证券",
                    "固收",
                    "利率债",
                    "政策转向",
                    "华兰生物",
                    "联得装备"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "固收",
                    "医药",
                    "装备制造"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【太平洋证券今日早读】固收：利率债短端机会更大，密切关注政策转向的可能性|华兰生物、联得装备公司点评20181015",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]